Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY antibody persistence study in previously vaccinated children
2014-005133-30Phase 3
- Sponsor
- Novartis
- Start
- Dec 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Meningococcal ACWY conjugate vaccine in meningococcal disease (2 cohorts), sponsored by Novartis. Primary endpoint: Percentage of subjects with hSBA titers >= 1:8 against meningococcal serogroups A, C, W-135, and Y at 40 months of age.
02
Drugs
Meningococcal ACWY conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2014-005133-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005133-30.